Insulet (US:PODD) ZACKS·2025-08-05 14:16Core Insights - Insulet (PODD) is expected to report quarterly earnings of $0.93 per share, a 69.1% increase year-over-year, with revenues projected at $615.49 million, reflecting a 26% year-over-year growth [1] Earnings Estimates - There has been a 0.2% upward revision in the consensus EPS estimate over the last 30 days, indicating analysts' reassessment of their forecasts [2] - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3] Revenue Projections - Analysts predict 'Revenue- Total Omnipod' at $605.82 million, showing a year-over-year change of +26.1% [5] - 'Revenue- Drug Delivery' is expected to be $9.07 million, indicating a +12% change from the prior-year quarter [5] - 'Revenue- International Omnipod' is forecasted to reach $171.85 million, suggesting a +34.2% year-over-year change [5] - 'Revenue- U.S. Omnipod' is estimated at $433.99 million, reflecting a +23.2% change from the year-ago quarter [6] Stock Performance - Insulet shares have decreased by -4.3% in the past month, contrasting with the Zacks S&P 500 composite's +1% performance [6] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [6]